Ketones, Muscle Metabolism, and SGLT2 Inhibitors

Purpose

Empagliflozin and other SGLT2 inhibitors are shown to markedly reduce cardiovascular mortality and hospitalization for heart failure (for both preserved and reduced ejection fraction- when the muscle of the left side of the heart is not pumping as well as normal in high-risk subjects with type 2 diabetes and without type 2 diabetes. We will study the relationship between the improvement in heart (cardiac and myocardial ketones) function after the treatment with Empagliflozin compared to baseline conditions. We will also study the relationship between the improvement in heart (cardiac and myocardial ketones) function after the treatment with Empagliflozin and the reduction of free fatty acids with Acipimox compared to baseline conditions

Category

• Muscle, Bone and Cartilage